JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Autor: Wu, Lin

4 záznamů v Medvik Filtry

Článek

Perioperative Nivolumab in Resectable Lung Cancer

Cascone, Tina
Autor Cascone, Tina From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Awad, Mark M
Autor Awad, Mark M From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Spicer, Jonathan D
Autor Spicer, Jonathan D From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
He, Jie
Autor He, Jie From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Lu, Shun
Autor Lu, Shun From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Sepesi, Boris
Autor Sepesi, Boris From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Tanaka, Fumihiro
Autor Tanaka, Fumihiro From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Taube, Janis M
Autor Taube, Janis M From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Cornelissen, Robin
Autor Cornelissen, Robin ORCID From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Havel, Libor
Autor Havel, Libor From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)

The New England journal of medicine. 2024 ; 390 (19) : 1756-1769. [pub] 20240516

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab may further improve clinical outcomes. METHODS: In this phase 3, randomized, double-blind trial, we assigned adults with resectable stage IIA to IIIB NSCLC to receive neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for 4 cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary outcome was event-free survival according to blinded independent review. Secondary outcomes were pathological complete response and major pathological response according to blinded independent review, overall survival, and safety. RESULTS: At this prespecified interim analysis (median follow-up, 25.4 months), the percentage of patients with 18-month event-free survival was 70.2% in the nivolumab group and 50.0% in the chemotherapy group (hazard ratio for disease progression or recurrence, abandoned surgery, or death, 0.58; 97.36% confidence interval [CI], 0.42 to 0.81; P<0.001). A pathological complete response occurred in 25.3% of the patients in the nivolumab group and in 4.7% of those in the chemotherapy group (odds ratio, 6.64; 95% CI, 3.40 to 12.97); a major pathological response occurred in 35.4% and 12.1%, respectively (odds ratio, 4.01; 95% CI, 2.48 to 6.49). Grade 3 or 4 treatment-related adverse events occurred in 32.5% of the patients in the nivolumab group and in 25.2% of those in the chemotherapy group. CONCLUSIONS: Perioperative treatment with nivolumab resulted in significantly longer event-free survival than chemotherapy in patients with resectable NSCLC. No new safety signals were observed. (Funded by Bristol Myers Squibb; CheckMate 77T ClinicalTrials.gov number, NCT04025879.).

Článek

Orientation selective DBS of entorhinal cortex and medial septal nucleus modulates activity of rat brain areas involved in memory and cognition

Scientific reports. 2022 ; 12 (1) : 8565. [pub] 20220520

Sci Rep
ISSN 2045-2322
Medvik
Zdroj

The recently introduced orientation selective deep brain stimulation (OS-DBS) technique freely controls the direction of the electric field's spatial gradient by using multiple contacts with independent current sources within a multielectrode array. The goal of OS-DBS is to align the electrical field along the axonal track of interest passing through the stimulation site. Here we utilized OS-DBS with a planar 3-channel electrode for stimulating the rat entorhinal cortex (EC) and medial septal nucleus (MSN), two promising areas for DBS treatment of Alzheimer's disease. The brain responses to OS-DBS were monitored by whole brain functional magnetic resonance imaging (fMRI) at 9.4 T with Multi-Band Sweep Imaging with Fourier Transformation (MB-SWIFT). Varying the in-plane OS-DBS stimulation angle in the EC resulted in activity modulation of multiple downstream brain areas involved in memory and cognition. Contrary to that, no angle dependence of brain activations was observed when stimulating the MSN, consistent with predictions based on the electrode configuration and on the main axonal directions of the targets derived from diffusion MRI tractography and histology. We conclude that tuning the OS-DBS stimulation angle modulates the activation of brain areas relevant to Alzheimer's disease, thus holding great promise in the DBS treatment of the disease.

MeSH
Alzheimerova nemoc * diagnostické zobrazování terapie MeSH
cortex entorhinalis diagnostické zobrazování fyziologie MeSH
hluboká mozková stimulace * metody MeSH
kognice MeSH
krysa rodu rattus MeSH
magnetická rezonanční tomografie metody MeSH
mozek MeSH
septální jádra * MeSH
zvířata MeSH
Check Tag
krysa rodu rattus MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
Research Support, N.I.H., Extramural MeSH

Článek

Brain fMRI during orientation selective epidural spinal cord stimulation

Scientific reports. 2021 ; 11 (1) : 5504. [pub] 20210309

Sci Rep
ISSN 2045-2322
Medvik
Zdroj

Epidural spinal cord stimulation (ESCS) is widely used for chronic pain treatment, and is also a promising tool for restoring motor function after spinal cord injury. Despite significant positive impact of ESCS, currently available protocols provide limited specificity and efficiency partially due to the limited number of contacts of the leads and to the limited flexibility to vary the spatial distribution of the stimulation field in respect to the spinal cord. Recently, we introduced Orientation Selective (OS) stimulation strategies for deep brain stimulation, and demonstrated their selectivity in rats using functional MRI (fMRI). The method achieves orientation selectivity by controlling the main direction of the electric field gradients using individually driven channels. Here, we introduced a similar OS approach for ESCS, and demonstrated orientation dependent brain activations as detected by brain fMRI. The fMRI activation patterns during spinal cord stimulation demonstrated the complexity of brain networks stimulated by OS-ESCS paradigms, involving brain areas responsible for the transmission of the motor and sensory information. The OS approach may allow targeting ESCS to spinal fibers of different orientations, ultimately making stimulation less dependent on the precision of the electrode implantation.

MeSH
epidurální prostor diagnostické zobrazování patofyziologie MeSH
implantované elektrody MeSH
krysa rodu rattus MeSH
magnetická rezonanční tomografie * MeSH
míšní stimulace * MeSH
poranění míchy * diagnostické zobrazování patofyziologie terapie MeSH
potkani Sprague-Dawley MeSH
zvířata MeSH
Check Tag
krysa rodu rattus MeSH
mužské pohlaví MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
Research Support, N.I.H., Extramural MeSH

Článek

Orientation selective deep brain stimulation of the subthalamic nucleus in rats

Neuroimage. 2020 ; 213 (-) : 116750. [pub] 20200318

ISSN 1095-9572
Medvik
Zdroj

Deep brain stimulation (DBS) has become an important tool in the management of a wide spectrum of diseases in neurology and psychiatry. Target selection is a vital aspect of DBS so that only the desired areas are stimulated. Segmented leads and current steering have been shown to be promising additions to DBS technology enabling better control of the stimulating electric field. Recently introduced orientation selective DBS (OS-DBS) is a related development permitting sensitization of the stimulus to axonal pathways with different orientations by freely controlling the primary direction of the electric field using multiple contacts. Here, we used OS-DBS to stimulate the subthalamic nucleus (STN) in healthy rats while simultaneously monitoring the induced brain activity with fMRI. Maximal activation of the sensorimotor and basal ganglia-thalamocortical networks was observed when the electric field was aligned mediolaterally in the STN pointing in the lateral direction, while no cortical activation was observed with the electric field pointing medially to the opposite direction. Such findings are consistent with mediolateral main direction of the STN fibers, as seen with high resolution diffusion imaging and histology. The asymmetry of the OS-DBS dipolar field distribution using three contacts along with the potential stimulation of the internal capsule, are also discussed. We conclude that OS-DBS offers an additional degree of flexibility for optimization of DBS of the STN which may enable a better treatment response.

MeSH
hluboká mozková stimulace metody MeSH
implantované elektrody * MeSH
krysa rodu rattus MeSH
magnetická rezonanční tomografie MeSH
nucleus subthalamicus fyziologie MeSH
potkani Sprague-Dawley MeSH
zvířata MeSH
Check Tag
krysa rodu rattus MeSH
mužské pohlaví MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
Research Support, N.I.H., Extramural MeSH

Kolekce

Publikováno

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH